头孢美唑和头孢西丁对产与非产超广谱β内酰胺酶菌株体外抗菌活性比较  

In vitro activity of cefmetazole against extended-spectrum beta-lactamases producing and non-producing strains: a comparison with cefoxitin

作　　者：郑沁[1] 康梅[1] 过孝静[1] 陈慧莉[1] 严可宁[1] 简军[1] 陈知行[1] 陈文昭[1] 吕晓菊[1] 

机构地区：[1]四川大学华西医院实验医学科临床微生物室,成都610041

出　　处：《中国感染与化疗杂志》2006年第1期50-52,共3页Chinese Journal of Infection and Chemotherapy

摘　　要：目的测定头孢美唑和头孢西丁对产ESBLs菌株的体外抗菌活性,并与非产ESBLs菌株的体外抗菌活性相比较。方法收集2004年1—12月华西医院各临床科室分离出的大肠埃希菌和肺炎克雷伯菌520株,采用Kirby-Bauer琼脂扩散法进行体外药敏试验并用表型确证试验检测ESBLs。结果筛选出产ESBLs菌226株,产酶菌检出率为43.5%,其中323株大肠埃希菌的ESBLs检出率为45.8%,197株肺炎克雷伯菌的ESBLs检出率为39.6%。头孢美唑对我院产ESBLs菌株体外抗菌活性优于头孢西丁。结论头霉素类抗生素可作为治疗产ESBLs菌株引起的感染的可选药物,但仍应参考药敏试验结果。我院分离的产ESBLs大肠埃希菌和肺炎克雷伯菌对头孢美唑的敏感性略优于头孢西丁。ObjectiveTo determine the in vitro antimicrobial activity of cefmetazole and cefoxitin against extended-spectrum beta-lactamases(ESBLs) producing and non-producing strains.MethodsA total of 520 strains of K.pneumoniae and E.coli were isolated from January 2004 to December 2004.Phenotypic confirmatory test was used to detect ESBLs.Kirby-Bauer agar diffusion method was used for susceptibility testing.ResultsOverall,226 ESBLs-producing strains were detected.The positive rate of ESBLs was 43.5%,specifically 45.8% among E.coli isolates and 39.6% among K.pneumoniae.In vitro antimicrobial activity of cefmetazole against ESBLs producing strains was higher than that of cefoxitin in West China Hospital.ConclusionsCephamycins can be the alternative treatment for ESBLs producing strains.The in vitro antimicrobial activity of cefmetazole against ESBLs producing strains is higher than that of cefoxitin in West China Hospital.

关 键 词：头孢美唑 头孢西丁 超广谱Β内酰胺酶 体外抗菌活性 

分 类 号：R96[医药卫生—药理学]